Comparative Pharmacology
Head-to-head clinical analysis: LABETALOL HYDROCHLORIDE versus MARCAINE HYDROCHLORIDE W EPINEPHRINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LABETALOL HYDROCHLORIDE versus MARCAINE HYDROCHLORIDE W EPINEPHRINE.
LABETALOL HYDROCHLORIDE vs MARCAINE HYDROCHLORIDE W/ EPINEPHRINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Labetalol is a non-selective beta-adrenoceptor blocker and selective alpha-1 adrenoceptor blocker. It reduces myocardial contractility, heart rate, and peripheral vascular resistance.
Bupivacaine is an amide local anesthetic that blocks sodium channels on neuronal membranes, inhibiting the initiation and propagation of nerve impulses. Epinephrine is a vasoconstrictor that prolongs the duration of action and reduces systemic absorption.
Oral: Initial 100 mg twice daily, titrate up to 200-400 mg twice daily; maximum 2400 mg/day. IV: 20 mg slow IV over 2 minutes, then 40-80 mg every 10 minutes as needed up to 300 mg total; or continuous IV infusion at 0.5-2 mg/min.
For local infiltration: 0.25-0.5% solution, up to 30 mL (75-175 mg bupivacaine) with epinephrine 1:200,000, not to exceed 3 mg/kg bupivacaine. For peripheral nerve block: 0.25-0.5% solution, up to 40 mL (100-200 mg). For epidural: 0.5% solution, 10-20 mL (50-100 mg). Maximum single dose: 225 mg with epinephrine.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours. In renal impairment, half-life may be slightly prolonged but not clinically significant; in hepatic impairment, half-life may be significantly prolonged.
Terminal elimination half-life in adults is 2.7–3.4 hours (mean ~3.0 h). In neonates, it is prolonged (8–12 hours) due to immature hepatic function. Clinically, this supports continuous infusion intervals of 6–12 hours for epidural analgesia.
Primarily hepatic metabolism; ~5% excreted unchanged in urine; ~55-60% as glucuronide conjugates in urine; fecal excretion <5%.
Bupivacaine is metabolized in the liver primarily via CYP3A4 and CYP1A2. Approximately 6% is excreted unchanged in urine. The major metabolite, pipecolylxylidine (PPX), is excreted renally (80–90% of dose) with 2–5% as desbutylbupivacaine. Fecal elimination accounts for <5%. Biliary excretion of metabolites occurs but is minimal.
Category A/B
Category A/B
Alpha/Beta-Blocker
Alpha/Beta Agonist